H.C. Wainwright Says CNTX Stock Drop Is 'Overdone' After CTIM-76 Ovarian Cancer Data

Context Therapeutics reported positive Phase 1 data for CTIM-76 in heavily pretreated platinum-resistant ovarian cancer, showing a 29% response rate and good safety, but the stock fell due to small trial size.